Innovent Biologics Inc.

OTC: IVBXF · Real-Time Price · USD
12.73
0.03 (0.24%)
At close: Aug 22, 2025, 12:53 PM

Innovent Biologics Income Statement

Financials in CNY. Fiscal year is January - December.
Fiscal Year Q4 2024 Q2 2024 Q4 2023 Q2 2023 Q4 2022 Q2 2022 Q4 2021 Q2 2021
Period Ending Dec 31, 2024 Jun 30, 2024 Dec 31, 2023 Jun 30, 2023 Dec 31, 2022 Jun 30, 2022 Dec 31, 2021 Jun 30, 2021
Revenue
5.47B 3.95B 3.5B 2.7B 2.32B 2.24B 2.33B 1.94B
Cost of Revenue
1.32B 1.09B 1.03B 781.76M 673.38M 708.38M 667.74M 556.68M
Gross Profit
4.15B 2.86B 2.48B 1.92B 1.64B 1.53B 1.66B 1.39B
Operating Income
-15.19M -740.69M -960.46M -718.85M -1.67B -1.45B -1.72B -981.35M
Interest Income
n/a n/a 48.33M 50.29M 132.41M n/a 142.8M n/a
Pretax Income
313.96M -392.58M -888.3M -256.11M -1.17B -998.91M -1.64B -1B
Net Income
297.99M -392.62M -888.76M -139.15M -1.23B -950.47M -1.73B -1B
Selling & General & Admin
2.89B 2.2B 2.14B 1.72B 1.62B 1.81B 2.03B 1.39B
Research & Development
1.28B 1.4B 1.3B 922.82M 1.7B 1.17B 1.35B 974.32M
Other Expenses
n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
4.17B 3.6B 3.44B 2.13B 2.95B 2.49B 3.41B 2.36B
Interest Expense
n/a n/a n/a n/a n/a 44.57M 112.51M 27.1M
Selling & Marketing Expenses
2.47B 1.88B 1.75B 1.35B 1.19B 1.4B 1.54B 1.08B
Cost & Expenses
5.48B 4.69B 4.46B 2.91B 3.62B 3.19B 4.08B 2.92B
Income Tax Expense
15.97M 35K 462K 116.96M 57.24M 48.44M 86.89M 152K
Shares Outstanding (Basic)
1.67B 1.62B 1.58B 1.54B 1.52B 1.46B 1.45B 1.45B
Shares Outstanding (Diluted)
1.63B 1.62B 1.58B 1.54B 1.52B 1.47B 1.46B 1.45B
EPS (Basic)
0.18 -0.24 -0.56 -0.09 -0.82 -0.64 -1.18 -0.7
EPS (Diluted)
0.18 -0.24 -0.56 -0.09 -0.82 -0.64 -1.18 -0.7
EBITDA
-231.41M -248.86M -741.75M -546.59M -1.53B -1.34B -1.63B -903.65M
EBIT
-323.55M -432.32M -845.1M -718.85M -1.67B -1.45B -1.72B -981.35M
Depreciation & Amortization
92.14M 183.46M 103.34M 172.25M 139.89M 105.2M 87.7M 77.7M